Literature DB >> 21885728

Validation of the pulmonary hypertension connection equation for survival prediction in pulmonary arterial hypertension.

Thenappan Thenappan1, Cherylanne Glassner1, Mardi Gomberg-Maitland2.   

Abstract

OBJECTIVE: The pulmonary hypertension connection (PHC) equation predicts contemporary survival in idiopathic, heritable, and anorexigen-associated pulmonary arterial hypertension (PAH). The aim of this study is to validate the PHC equation in a prospective PAH population cohort and compare its predictability with the French equation.
METHODS: We compared the rates of actual survival in patients prospectively followed for up to 3.5 years in four double-blind, randomized trials and their open-label extension studies with predicted survival calculated using the PHC equation [(P(t) = e((-A(x,y,z)t)), A(x,y,z) = e((-1.270-0.0148x + 0.0402y - 0.361z)), where P(t) is the probability of survival, t the time interval in years, x the mean pulmonary artery pressure, y the mean right atrial pressure, and z the cardiac index] and the French equation in patients with idiopathic, heritable, and anorexigen-associated PAH (n = 449).
RESULTS: Mean age was 44 ± 15 years, 77% were women, and 80% had World Health Organization (WHO) functional class III/IV symptoms. The mean 6-min walk distance (6MWD) was 354 ± 95 m. The baseline hemodynamics were as follows: mean right atrial pressure 10 ± 6 mm Hg, mean pulmonary artery pressure 59 ± 15 mm Hg, and cardiac output 4.1 ± 1.5 L/min. The 1-, 2-, and 3-year Kaplan-Meier survival rates were 89%, 80%, and 70%, respectively; the nonadjusted survival rates were 91%, 87%, and 84%, respectively. The expected survival predicted by both the PHC and the French equations was similar to the actual observed Kaplan-Meier survival and was within its 95% confidence limits. The PHC equation also performed well when used in patients with WHO functional class III/IV, cardiac output < 4 L/min, or 6MWD < 380 m.
CONCLUSION: Risk prediction equations (PHC and French) accurately predicted survival and may be useful for risk estimation in patients with idiopathic, heritable, and anorexigen-associated PAH in large cohort studies. Their use for survival prediction for individual patients needs further study.

Entities:  

Mesh:

Year:  2011        PMID: 21885728     DOI: 10.1378/chest.11-0969

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  24 in total

Review 1.  Current clinical management of pulmonary arterial hypertension.

Authors:  Roham T Zamanian; Kristina T Kudelko; Yon K Sung; Vinicio de Jesus Perez; Juliana Liu; Edda Spiekerkoetter
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

2.  Shorter survival in familial versus idiopathic pulmonary arterial hypertension is associated with hemodynamic markers of impaired right ventricular function.

Authors:  Evan L Brittain; Meredith E Pugh; Lisa A Wheeler; Ivan M Robbins; James E Loyd; John H Newman; Emma K Larkin; Eric D Austin; Anna R Hemnes
Journal:  Pulm Circ       Date:  2013-12-03       Impact factor: 3.017

3.  Clinical and Echocardiographic Predictors of Outcomes in Patients With Pulmonary Hypertension.

Authors:  Irfan Siddiqui; Sudarshan Rajagopal; Amanda Brucker; Karen Chiswell; Bridgette Christopher; Fawaz Alenezi; Aditya Mandawat; Danny Rivera; Kristine Arges; Victor Tapson; Joseph Kisslo; Eric Velazquez; Pamela S Douglas; Zainab Samad
Journal:  Am J Cardiol       Date:  2018-06-15       Impact factor: 2.778

4.  Decreased pulmonary arterial proportional pulse pressure is associated with increased mortality in group 1 pulmonary hypertension.

Authors:  Hunter Mwansa; Kenneth C Bilchick; Alex M Parker; William Harding; Benjamin Ruth; Jamie L W Kennedy; Manu Mysore; Younghoon Kwon; Andrew Mihalek; Sula Mazimba
Journal:  Clin Cardiol       Date:  2017-07-10       Impact factor: 2.882

5.  Sodium tanshinone IIA sulfonate inhibits hypoxia-induced enhancement of SOCE in pulmonary arterial smooth muscle cells via the PKG-PPAR-γ signaling axis.

Authors:  Qian Jiang; Wenju Lu; Kai Yang; Cyrus Hadadi; Xin Fu; Yuqin Chen; Xin Yun; Jie Zhang; Meichan Li; Lei Xu; Haiyang Tang; Jason X-J Yuan; Jian Wang; Dejun Sun
Journal:  Am J Physiol Cell Physiol       Date:  2016-05-18       Impact factor: 4.249

6.  Sodium tanshinone IIA sulfonate inhibits canonical transient receptor potential expression in pulmonary arterial smooth muscle from pulmonary hypertensive rats.

Authors:  Jian Wang; Qian Jiang; Limei Wan; Kai Yang; Yi Zhang; Yuqin Chen; Elizabeth Wang; Ning Lai; Lei Zhao; Hua Jiang; Yueqian Sun; Nanshan Zhong; Pixin Ran; Wenju Lu
Journal:  Am J Respir Cell Mol Biol       Date:  2012-10-11       Impact factor: 6.914

7.  Left Ventricular Myocardial Function in Children With Pulmonary Hypertension: Relation to Right Ventricular Performance and Hemodynamics.

Authors:  Dale A Burkett; Cameron Slorach; Sonali S Patel; Andrew N Redington; D Dunbar Ivy; Luc Mertens; Adel K Younoszai; Mark K Friedberg
Journal:  Circ Cardiovasc Imaging       Date:  2015-08       Impact factor: 7.792

8.  Benefits of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension.

Authors:  Leighton Chan; Lisa M K Chin; Michelle Kennedy; Joshua G Woolstenhulme; Steven D Nathan; Ali A Weinstein; Gerilynn Connors; Nargues A Weir; Bart Drinkard; James Lamberti; Randall E Keyser
Journal:  Chest       Date:  2013-02-01       Impact factor: 9.410

9.  Tetramethylpyrazine: A promising drug for the treatment of pulmonary hypertension.

Authors:  Yuqin Chen; Wenju Lu; Kai Yang; Xin Duan; Mengxi Li; Xiuqing Chen; Jie Zhang; Meidan Kuang; Shiyun Liu; Xiongting Wu; Guofa Zou; Chunli Liu; Cheng Hong; Wenjun He; Jing Liao; Chi Hou; Zhe Zhang; Qiuyu Zheng; Jiyuan Chen; Nuofu Zhang; Haiyang Tang; Rebecca R Vanderpool; Ankit A Desai; Franz Rischard; Stephen M Black; Joe G N Garcia; Ayako Makino; Jason X-J Yuan; Nanshan Zhong; Jian Wang
Journal:  Br J Pharmacol       Date:  2020-04-27       Impact factor: 8.739

10.  The right ventricle explains sex differences in survival in idiopathic pulmonary arterial hypertension.

Authors:  Wouter Jacobs; Mariëlle C van de Veerdonk; Pia Trip; Frances de Man; Martijn W Heymans; Johannes T Marcus; Steven M Kawut; Harm-Jan Bogaard; Anco Boonstra; Anton Vonk Noordegraaf
Journal:  Chest       Date:  2014-06       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.